Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement
Osteoporosis is a chronic disease requiring long-term treatment aimed at reducing the risk of low-energy fractures, by improving the quality and strength of bones when taking this or that drug. Bisphosphonates (BPs) are deposited in the bone, so that they have an aftereffect. Due to the increased ri...
Main Author: | N. V. Toroptsova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/863 |
Similar Items
-
Duration of treatment for osteoporosis
by: Luca Idolazzi, et al.
Published: (2013-03-01) -
THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01) -
Treatment of osteoporosis in patients who had low-energy fractures: challenges of diagnosis and commitment to pathogenetic treatment
by: O. V. Dobrovolskaya, et al.
Published: (2018-05-01) -
Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01) -
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)